1-Aminomethyl-5-methoxyindane

1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity to DFMDA.[1][2]

1-Aminomethyl-5-methoxyindane

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (5-Methoxy-2,3-dihydro-1H-inden-1-yl)methanamine
CAS Number	1415750-28-5^N
PubChem CID	45091234
ChemSpider	24205063^Y
Chemical and physical data
Formula	C11H15NO
Molar mass	177.247 g·mol^−1
3D model (JSmol)	Interactive image
SMILES NCC1CCc2c1ccc(OC)c2
InChI InChI=1S/C11H15NO/c1-13-10-4-5-11-8(6-10)2-3-9(11)7-12/h4-6,9H,2-3,7,12H2,1H3^Y Key:WPBKCMLYKMDWRD-UHFFFAOYSA-N^Y
^NY (what is this?)  (verify)

See also

• 2CB-Ind

References

1. Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL (February 2004). "Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 679–87. doi:10.1124/jpet.103.057836. PMID 14593087.
2. Walline CC, Nichols DE, Carroll FI, Barker EL (June 2008). "Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 791–800. doi:10.1124/jpet.108.136200. PMC 2637348. PMID 18354055.